SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
1352458508091368v1
14/7/981    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sellner, J
Right arrow Articles by Mattle, H P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sellner, J
Right arrow Articles by Mattle, H P
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis

J Sellner1, I Greeve2, and H P Mattle2

1 Department of Neurology, Inselspital Bern University Hospital, and University of Bern, Bern, Switzerland; Department of Neurology, Klinikum rechts der Isar Technische Universität München, München, Germany
2 Department of Neurology, Inselspital Bern University Hospital, and University of Bern, Bern, Switzerland

* To whom correspondence should be addressed.


   Abstract

The anti-inflammatory potential of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, as reflected by modulation of C-reactive protein (CRP), might be beneficial in the treatment of patients with multiple sclerosis (MS). We evaluated serum levels of high-sensitivity (hs)-CRP in relapsing–remitting MS patients receiving interferon-{beta} 1b and atorvastatin as add-on therapy. This study shows that interferon-{beta} treatment is associated with increased serum levels of hs-CRP in MS patients (P < 0.01). In contrast, when atorvastatin is added to interferon-{beta}, hs-CRP serum levels decrease to the normal range (P < 0.05), indicating an anti-inflammatory action of atorvastatin in MS. However, whether add-on treatment with atorvastatin modifies the course of MS remains to be investigated.

Key Words: anti-inflammatory, atorvastatin, C-reactive protein, multiple sclerosis

First published on June 23, 2008, doi:10.1177/1352458508091368

Multiple Sclerosis 2008;14:981.

A more recent version of this article appeared on August 1, 2008


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement